个人中心 - 老虎社区

章超

IP属地：浙江

帖子 · 3帖子 · 3
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 章超章超
  ·2023-03-20
  $上证指数(000001.SH)$
  111 评论
  点赞
  分享
  举报
- 章超章超
  ·2022-10-24
  说说你对这篇新闻的看法...
  贵州茅台跌破1500元，尾盘跌幅扩大至近8%
  10月24日，贵州茅台跌破1500元，尾盘跌幅扩大至近8%。
  贵州茅台跌破1500元，尾盘跌幅扩大至近8%
  1,166 1
  1
  分享
  举报
- 章超章超
  ·2021-08-08
  chiffanmle
  国泰君安：维持我武生物(300357.SZ)“增持”评级上调目标价至85元
  智通财经APP获悉，国泰君安发布研究报告称，考虑到我武生物现有的粉尘螨滴剂的快速恢复，以及蒿草花粉未来的增量，上调21年EPS为0.66元，考虑到未来销售费用增加及干细胞研发投入加大，略微下调2022-23年预测EPS至0.85/1.12元元，公司深耕脱敏利基市场，为大蓝海里的小龙头，参考行业平均估值并给予一定龙头溢价，给予22年PE100倍，上调目标价至85元，维持“增持”评级。国泰君安主要观点如下：二季度收入利润恢复加速。
  国泰君安：维持我武生物(300357.SZ)“增持”评级上调目标价至85元
  401 评论
  点赞
  分享
  举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2025 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3520092514185296","uuid":"3520092514185296","gmtCreate":1556998492374,"gmtModify":1556998492374,"name":"章超","pinyin":"zczhangchao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":4,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":650211626,"gmtCreate":1679296286465,"gmtModify":1679297973505,"author":{"id":"3520092514185296","authorId":"3520092514185296","name":"章超","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3520092514185296","authorIdStr":"3520092514185296"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/000001.SH\">$上证指数(000001.SH)$&nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/000001.SH\">$上证指数(000001.SH)$&nbsp;</a>","text":"$上证指数(000001.SH)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/650211626","isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":662281471,"gmtCreate":1666594256293,"gmtModify":1666595443545,"author":{"id":"3520092514185296","authorId":"3520092514185296","name":"章超","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3520092514185296","authorIdStr":"3520092514185296"},"themes":[],"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/662281471","repostId":"1180616240","repostType":2,"repost":{"id":"1180616240","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1666593951,"share":"https://www.laohu8.com/m/news/1180616240?lang=&edition=full","pubTime":"2022-10-24 14:45","market":"sh","language":"zh","title":"贵州茅台跌破1500元，尾盘跌幅扩大至近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180616240","media":"老虎资讯综合","summary":"10月24日，贵州茅台跌破1500元，尾盘跌幅扩大至近8%。","content":"<html><head></head><body><p>10月24日，<a href=\"https://laohu8.com/S/600519\">贵州茅台</a>跌破1500元，尾盘跌幅扩大至近8%。</p><p><img src=\"https://static.tigerbbs.com/4a339c6c4be6de8c5689d72cd790fd04\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>贵州茅台跌破1500元，尾盘跌幅扩大至近8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n贵州茅台跌破1500元，尾盘跌幅扩大至近8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2022-10-24 14:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>10月24日，<a href=\"https://laohu8.com/S/600519\">贵州茅台</a>跌破1500元，尾盘跌幅扩大至近8%。</p><p><img src=\"https://static.tigerbbs.com/4a339c6c4be6de8c5689d72cd790fd04\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/aba16b4f88c90908701f4ff26fee613c","relate_stocks":{"600519":"贵州茅台","LU0048580855.USD":"富达大中华区A","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU1439103000.SGD":"Fidelity Greater China Multi Asset Growth & Income A-MINCOME(G)-SGD","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK0187":"一线龙头","LU1720050803.USD":"安联全方位中国股票基金","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU1105468828.SGD":"Allianz Total Return Asian Equity AM DIS H2-SGD","BK0175":"白马股","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0348814723.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"A\" (USD) INC  NC","LU0878005551.USD":"UBS (LUX) KEY SELEC ASIA ALLOCATION OPPORTUNITY (USD) \"P\" (USD) ACC","LU0651946864.USD":"贝莱德新兴市场股票收益A2","LU0359201612.USD":"贝莱德中国基金A2","LU1051768304.USD":"贝莱德新兴市场股票收益A6","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180616240","content_text":"10月24日，贵州茅台跌破1500元，尾盘跌幅扩大至近8%。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1166,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":891243863,"gmtCreate":1628394844352,"gmtModify":1628394844352,"author":{"id":"3520092514185296","authorId":"3520092514185296","name":"章超","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3520092514185296","authorIdStr":"3520092514185296"},"themes":[],"htmlText":"chiffanmle","listText":"chiffanmle","text":"chiffanmle","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/891243863","repostId":"2153661976","repostType":2,"repost":{"id":"2153661976","kind":"news","pubTimestamp":1626846023,"share":"https://www.laohu8.com/m/news/2153661976?lang=&edition=full","pubTime":"2021-07-21 13:40","market":"hk","language":"zh","title":"国泰君安：维持我武生物(300357.SZ)“增持”评级 上调目标价至85元","url":"https://stock-news.laohu8.com/highlight/detail?id=2153661976","media":"智通财经","summary":"智通财经APP获悉，国泰君安发布研究报告称，考虑到我武生物现有的粉尘螨滴剂的快速恢复，以及蒿草花粉未来的增量，上调21年EPS为0.66元，考虑到未来销售费用增加及干细胞研发投入加大，略微下调2022-23年预测EPS至0.85/1.12元元，公司深耕脱敏利基市场，为大蓝海里的小龙头，参考行业平均估值并给予一定龙头溢价，给予22年PE100倍，上调目标价至85元，维持“增持”评级。国泰君安主要观点如下：二季度收入利润恢复加速。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/601211\">国泰君安</a>发布研究报告称，考虑到<a href=\"https://laohu8.com/S/300357\">我武生物</a>(300357.SZ)现有的粉尘螨滴剂的快速恢复，以及蒿草花粉未来的增量，上调21年EPS为0.66元(原为0.65元)，考虑到未来销售费用增加及干细胞研发投入加大，略微下调2022-23年预测EPS至0.85/1.12元(原为0.86/1.14)元，公司深耕脱敏利基市场，为大蓝海里的小龙头，参考行业平均估值并给予一定龙头溢价，给予22年PE100倍，上调目标价至85元，维持“增持”评级。</p><p>公司发布业绩快报，2021H1实现收入3.48亿元，同比增长33.99%，实现归母净利润1.47亿元，同比增长37.61%，公司收入及利润快速增长，业绩恢复趋势显著。</p><p><strong><a href=\"https://laohu8.com/S/02611\">国泰君安</a>主要观点如下：</strong></p><p><strong>二季度收入利润恢复加速。</strong>公司21Q2单季度收入同比增长23%，考虑到去年Q2在疫情影响下仍做到9.5%的收入增速，且2021Q2疫情反复，公司21Q2环比增长已能体现较好恢复态势和患者粘性。若以2019年为基数计算，则21Q1、21Q2收入端增速分别为19%、34%，归母净利润端增速分别为7%、19%，环比恢复态势更趋显著。</p><p>新产品蒿草花粉滴剂目前仍在进院阶段，已完成多个北方省份的挂网，由于每年花粉季在7-9月份，且患者需提前用药，该行认为蒿草花粉销售贡献将在2022年有更明显的体现。考虑到蒿草花粉过敏药物此前空白，且公司已有一定的北方销售基础和脱敏推广经营，预计蒿草花粉的峰值和爬坡速度快于预期。</p><p><strong>催化剂：</strong>市场拓展超预期;新产品获批上市。</p><p><strong>风险提示：</strong>药品放量不及预期;新药研发投入的不确定性风险。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国泰君安：维持我武生物(300357.SZ)“增持”评级 上调目标价至85元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国泰君安：维持我武生物(300357.SZ)“增持”评级 上调目标价至85元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 13:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/518217.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国泰君安发布研究报告称，考虑到我武生物(300357.SZ)现有的粉尘螨滴剂的快速恢复，以及蒿草花粉未来的增量，上调21年EPS为0.66元(原为0.65元)，考虑到未来销售费用增加及干细胞研发投入加大，略微下调2022-23年预测EPS至0.85/1.12元(原为0.86/1.14)元，公司深耕脱敏利基市场，为大蓝海里的小龙头，参考行业平均估值并给予一定龙头溢价，给予22年...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/518217.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b35a217d7028f5445b1c4d5f03465791","relate_stocks":{"300357":"我武生物","02611":"国泰君安"},"source_url":"http://www.zhitongcaijing.com/content/detail/518217.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153661976","content_text":"智通财经APP获悉，国泰君安发布研究报告称，考虑到我武生物(300357.SZ)现有的粉尘螨滴剂的快速恢复，以及蒿草花粉未来的增量，上调21年EPS为0.66元(原为0.65元)，考虑到未来销售费用增加及干细胞研发投入加大，略微下调2022-23年预测EPS至0.85/1.12元(原为0.86/1.14)元，公司深耕脱敏利基市场，为大蓝海里的小龙头，参考行业平均估值并给予一定龙头溢价，给予22年PE100倍，上调目标价至85元，维持“增持”评级。公司发布业绩快报，2021H1实现收入3.48亿元，同比增长33.99%，实现归母净利润1.47亿元，同比增长37.61%，公司收入及利润快速增长，业绩恢复趋势显著。国泰君安主要观点如下：二季度收入利润恢复加速。公司21Q2单季度收入同比增长23%，考虑到去年Q2在疫情影响下仍做到9.5%的收入增速，且2021Q2疫情反复，公司21Q2环比增长已能体现较好恢复态势和患者粘性。若以2019年为基数计算，则21Q1、21Q2收入端增速分别为19%、34%，归母净利润端增速分别为7%、19%，环比恢复态势更趋显著。新产品蒿草花粉滴剂目前仍在进院阶段，已完成多个北方省份的挂网，由于每年花粉季在7-9月份，且患者需提前用药，该行认为蒿草花粉销售贡献将在2022年有更明显的体现。考虑到蒿草花粉过敏药物此前空白，且公司已有一定的北方销售基础和脱敏推广经营，预计蒿草花粉的峰值和爬坡速度快于预期。催化剂：市场拓展超预期;新产品获批上市。风险提示：药品放量不及预期;新药研发投入的不确定性风险。","news_type":1},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}